热休克蛋白 90(Hsp90)/细胞分裂周期蛋白 37(Cdc37)伴侣蛋白/共伴侣蛋白复合物,通过草药药物 Withaferin A 的作用模式阐明的新型连接点抗癌靶标。

Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.

机构信息

Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India.

出版信息

BMC Bioinformatics. 2011 Feb 15;12 Suppl 1(Suppl 1):S30. doi: 10.1186/1471-2105-12-S1-S30.

Abstract

BACKGROUND

HSPs (Heat shock proteins) are highly conserved ubiquitous proteins among species which are involved in maintaining appropriate folding and conformation of other proteins and are thus referred to as molecular chaperones. Hsp90 (Heat-shock protein 90 kDa) is one of a group of molecular chaperones responsible for managing protein folding and quality control in cell environment. However it is also involved in the maturation and stabilization of a wide range of oncogenic client proteins which are crucial for oncogenesis and malignant progression. Hsp90 requires a series of co-chaperones to assemble into a super-chaperone complex for its function. These co-chaperones bind and leave the complex at various stages to regulate the chaperoning process. Arresting the chaperone cycle at these stages by targeting different co-chaperone/Hsp90 interactions seems to be quite a viable alternative and is likely to achieve similar consequences as that of Hsp90 direct inhibition with added favors of high specificity and reduced side effect profile. The study conducted here is an attempt to explore the potential of Withania somnifera's major constituent WA (Withaferin A) in attenuating the Hsp90/Cdc37 chaperone/co-chaperone interactions for enhanced tumor arresting activity and to elucidate the underlying mode of action using computational approaches.

RESULTS

Formation of active Hsp90/Cdc37 complex is one of the essential steps for facilitation of chaperone client interaction, non-assembly of which can lead to prevention of the chaperone-client association resulting in apoptosis of tumor cells. From our flexible docking analysis of WA into active Hsp90/Cdc37 complex in which key interfacing residues of the complex were kept flexible, disruption of the active association complex can be discerned. While docking of WA into segregated Hsp90 leaves the interface residues untouched. Thus the molecular docking analysis of WA into Hsp90 and active Hsp90/Cdc37 complex conducted in this study provides significant evidence in support of the proposed mechanism of chaperone assembly suppression by inhibition or disruption of active Hsp90/Cdc37 complex formation being accounted by non-assembly of the catalytically active Hsp90/Cdc37 complex. Results from the molecular dynamics simulations in water show that the trajectories of the protein complexed with ligand WA are stable over a considerably long time period of 4 ns, with the energies of the complex being lowered in comparison to the un-docked association complex, suggesting the thermodynamic stability of WA complexed Hsp90/Cdc37.

CONCLUSIONS

The molecular chaperone Hsp90 has been a promising target for cancer therapy. Cancer is a disease marked by genetic instability. Thus specific inhibition of individual proteins or signalling pathways holds a great potential for subversion of this genetic plasticity of cancers. This study is a step forward in this direction. Our computational analysis provided a rationalization to the ability of naturally occurring WA to alter the chaperone signalling pathway. The large value of binding energy involved in binding of WA to the active Hsp90/Cdc37 complex consolidates the thermodynamic stability of the binding. Our docking results obtained substantiate the hypothesis that WA has the potential to inhibit the association of chaperone (Hsp90) to its co-chaperone (Cdc37) by disrupting the stability of attachment of Hsp90 to Cdc37. Conclusively our results strongly suggest that withaferin A is a potent anticancer agent as ascertained by its potent Hsp90-client modulating capability.

摘要

背景

热休克蛋白(HSPs)是物种间高度保守的普遍存在的蛋白质,它们参与维持其他蛋白质的适当折叠和构象,因此被称为分子伴侣。Hsp90(热休克蛋白 90kDa)是负责管理细胞环境中蛋白质折叠和质量控制的分子伴侣之一。然而,它也参与了广泛的致癌客户蛋白的成熟和稳定,这些蛋白对于肿瘤发生和恶性进展至关重要。Hsp90 需要一系列共伴侣来组装成超级伴侣复合物以发挥其功能。这些共伴侣在不同阶段结合和离开复合物,以调节伴侣过程。通过靶向不同的共伴侣/Hsp90 相互作用来阻止伴侣周期,似乎是一种可行的替代方法,并且可能会产生与直接抑制 Hsp90 相似的结果,同时具有更高的特异性和减少的副作用。本研究试图探索印度人参的主要成分 WA(Withaferin A)在减弱 Hsp90/Cdc37 伴侣/共伴侣相互作用方面的潜力,以增强肿瘤抑制活性,并使用计算方法阐明潜在的作用机制。

结果

形成活性 Hsp90/Cdc37 复合物是促进伴侣-客户相互作用的必要步骤之一,复合物的非组装可能导致伴侣-客户关联的预防,从而导致肿瘤细胞凋亡。从我们对 WA 进入活性 Hsp90/Cdc37 复合物的灵活对接分析来看,复合物的关键界面残基保持灵活,可以发现活性复合物的破坏。而 WA 进入分离的 Hsp90 不会影响界面残基。因此,本研究中对 Hsp90 和活性 Hsp90/Cdc37 复合物进行的 WA 分子对接分析提供了重要证据,支持了所提出的通过抑制或破坏活性 Hsp90/Cdc37 复合物的形成来抑制伴侣组装的机制,这是由于催化活性 Hsp90/Cdc37 复合物的非组装所致。在水中进行的分子动力学模拟结果表明,与配体 WA 复合的蛋白质复合物的轨迹在相当长的 4 纳秒时间内是稳定的,与未对接的关联复合物相比,复合物的能量降低,这表明 WA 复合 Hsp90/Cdc37 的热力学稳定性。

结论

分子伴侣 Hsp90 一直是癌症治疗的一个有前途的靶点。癌症是一种以遗传不稳定性为特征的疾病。因此,特异性抑制单个蛋白质或信号通路对于颠覆癌症的这种遗传可塑性具有很大的潜力。这项研究是朝这个方向迈出的一步。我们的计算分析为天然存在的 WA 改变伴侣信号通路的能力提供了合理化解释。WA 与活性 Hsp90/Cdc37 复合物结合所涉及的结合能值很大,巩固了结合的热力学稳定性。我们的对接结果证实了这样一种假设,即 WA 有可能通过破坏 Hsp90 与 Cdc37 结合的稳定性来抑制伴侣(Hsp90)与共伴侣(Cdc37)的结合。总之,我们的结果强烈表明,正如其对 Hsp90 客户的调制能力所证实的那样,Withaferin A 是一种有效的抗癌药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e228/3044286/627568e5ae8a/1471-2105-12-S1-S30-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索